Healthcare >> Analyst Interviews >> October 5, 2018
Clinical Trial Readouts on the Horizon for NASH Monotherapies
Steven Seedhouse, Ph.D., is Vice President, Equity Research, Biotechnology at Raymond James Financial, Inc. Dr. Seedhouse has been a biotech equity research analyst or an associate at various firms since 2015. He joined Raymond James in March 2018. Prior to his career in equity research, Dr. Seedhouse completed a Ph.D. in pharmacology from Roswell Park Cancer Institute in Buffalo, New York, and holds an M.S. in medicinal chemistry from SUNY Buffalo. Profile
Word count: 4,014
TWST: Can you describe what your universe of coverage is at this time?
Dr. Seedhouse: I cover 11 companies in total currently. One of them is